Abstract
Pancreatic cancer (PC) is typically a fatal disease due to its rapid growth and the lack of early diagnostic techniques. Because approximately 10% of PCs are attributable to a hereditary susceptibility, identifying and studying patients with a family history of PC or known genetic predisposition to PC can improve the prevention, diagnosis, and treatment of PC. A skilled team of study investigators, physicians, genetic counselors, and data managers must work with patients and families to confidentially store and organize data from PC patients and high-risk patients. This data, collected in conjunction with patients’ tissue and blood specimens, will contribute to the understanding of the biology, etiology, and epidemiology of PC, and can ultimately improve screening and management for patients with an underlying hereditary predisposition to PC.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59:99–111
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012
Brand RE et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469
Kohler BA et al (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736
Langer P et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410–1418
Verna EC et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037
Kimmey MB et al (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56:S82–S86
Canto MI et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2:606–621
Poley JW et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181
Ghadirian P et al (1991) Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 10:183–196
Tersmette AC et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744
Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF Jr (1988) Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 128:324–336
Fernandez E, La Vecchia C, D’Avanzo B, Negri E, Franceschi S (1994) Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3:209–212
Silverman DT, Schiffman M, Everhart J, Goldstein A et al (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80:1830–1837
Grover S, Syngal S (2010) Hereditary pancreatic cancer. Gastroenterology 139:1076–1080, 1080 e1071-1072
Lynch HT, Fusaro RM (1991) Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6:127–131
Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447–1453
Lowenfels AB, Maisonneuve P, DiMagno EP et al (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89:442–446
Schneider R, Slater EP, Sina M et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10:323–330
Jones S, Hruban RH, Kamiyama M, Borges M et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217
Lynch HT, Smyrk T, Kern SE, Hruban RH et al (1996) Familial pancreatic cancer: a review. Semin Oncol 23:251–275
Evans JP, Burke W, Chen R, Bennett RL et al (1995) Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 32:330–335
Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23
Hahn SA, Greenhalf B, Ellis I, Sina-Frey M et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221
Lynch HT, Brand RE, Deters CA et al (2001) Hereditary pancreatic cancer. Pancreatology 1:466–471
Applebaum SE, Kant JA, Whitcomb DC, Ellis IH (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588, viii
Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM (2002) Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 23:133–149
Schenk M, Schwartz AG, O’Neal E, Kinnard M et al (2001) Familial risk of pancreatic cancer. J Natl Cancer Inst 93:640–644
Real FX (2003) A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 124:1958–1964
Hruban RH, Adsay NV, Albores-Saavedra J, Compton C et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586
Del Chiaro M, Zerbi A, Capurso G, Zamboni G et al (2010) Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis 42:597–605
Brune K, Abe T, Canto M, O’Malley L, Klein AP et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30:1067–1076
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32
Tanaka M, Fernandez-del Castillo C, Adsay V, et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183–97.
Sipos B, Frank S, Gress T, Hahn S, Kloppel G (2009) Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9:45–54
Ariyama J, Suyama M, Satoh K, Sai J (1998) Imaging of small pancreatic ductal adenocarcinoma. Pancreas 16:396–401
Hudson KL (2011) Genomics, health care, and society. N Engl J Med 365:1033–1041
Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2012
O.H.R.P 2008 Protections. Guidance on Research Involving Coded Private Information or Biological Specimens
Farnell MB (2008) Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg 12:414–416
Walsh RM, Henderson JM, Vogt DP, Baker ME et al (2002) Prospective preoperative determination of mucinos pancreatic cystic neoplasms. Surgery 132:628–633, discussion 633–624
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lucas, A.L., Chang, M.M., Lipsyc, M.D., Frucht, H. (2013). The Prevention and Genetics of Pancreatic Cancer: A Programmatic Approach. In: Su, G. (eds) Pancreatic Cancer. Methods in Molecular Biology, vol 980. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-287-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-62703-287-2_10
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-286-5
Online ISBN: 978-1-62703-287-2
eBook Packages: Springer Protocols